Key Takeaways
- • FDA issued a Warning Letter to Platinum Biologics LLC on August 15, 2025, citing violations of section 505(a) of the Federal Food, Drug, and Cosmetic Act and section 351(a)(1) of the Public Health Service Act for marketing four unapproved biologics products.
- • Four products targeted in the warning: Nano PRP Jelly, Nano Flex, NanoEx, and Nano Xsomes—all marketed for allogeneic use without approved Biologics License Applications (BLAs) or New Drug Applications (NDAs).
- • Regulatory violation centers on unlicensed biological products and unapproved new drugs, making interstate commerce of these products illegal under federal law; the company lacks applicable exceptions under 21 CFR 1271.15 and fails to meet criteria under 21 CFR 1271.10(a).
- • Company operates as a physician-centric Group Purchasing Organization (GPO) specializing in biologics solutions, with headquarters in Orlando, Florida; Beeben Russell serves as Chairman of the Board.
- • Warning carries significant compliance implications for the regenerative medicine sector, signaling heightened FDA enforcement scrutiny on umbilical cord-derived and exosome products marketed without proper regulatory authorization.
Summary
The U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) issued a formal Warning Letter to Platinum Biologics LLC on August 15, 2025, identifying serious regulatory violations related to the unauthorized marketing of four biological products. The FDA determined that Nano PRP Jelly, Nano Flex, NanoEx, and Nano Xsomes—all umbilical cord-derived and exosome-based products marketed for allogeneic use—constitute unlicensed biological products and unapproved new drugs in violation of federal law.
According to the FDA's official correspondence, addressed to Platinum Biologics Chairman Beeben Russell, the products violate section 505(a) of the Federal Food, Drug, and Cosmetic Act and section 351(a)(1) of the Public Health Service Act. The agency found that while biological products with approved Biologics License Applications are exempt from the requirement for New Drug Applications under section 505, no such exemptions apply to Platinum Biologics' offerings. The company fails to qualify for any exception under 21 CFR 1271.15, and its products do not meet the criteria established in 21 CFR 1271.10(a), the regulatory standard governing tissue products and cellular therapies.
Platinum Biologics, based in Orlando, Florida, operates as a physician-centric Group Purchasing Organization specializing in tailored biologics solutions. The Warning Letter prohibits the introduction or delivery of these products into interstate commerce under section 301(d) of the FD&C Act. This enforcement action underscores intensified FDA regulatory scrutiny within the regenerative medicine and perinatal biologics sector, particularly regarding stem cell-derived and exosome products that lack proper authorization pathways. The warning has implications across the industry for manufacturers and distributors of similar umbilical cord and exosome-based therapeutics.
According to the FDA's official correspondence, addressed to Platinum Biologics Chairman Beeben Russell, the products violate section 505(a) of the Federal Food, Drug, and Cosmetic Act and section 351(a)(1) of the Public Health Service Act. The agency found that while biological products with approved Biologics License Applications are exempt from the requirement for New Drug Applications under section 505, no such exemptions apply to Platinum Biologics' offerings. The company fails to qualify for any exception under 21 CFR 1271.15, and its products do not meet the criteria established in 21 CFR 1271.10(a), the regulatory standard governing tissue products and cellular therapies.
Platinum Biologics, based in Orlando, Florida, operates as a physician-centric Group Purchasing Organization specializing in tailored biologics solutions. The Warning Letter prohibits the introduction or delivery of these products into interstate commerce under section 301(d) of the FD&C Act. This enforcement action underscores intensified FDA regulatory scrutiny within the regenerative medicine and perinatal biologics sector, particularly regarding stem cell-derived and exosome products that lack proper authorization pathways. The warning has implications across the industry for manufacturers and distributors of similar umbilical cord and exosome-based therapeutics.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.